Abiopharma

🔍 Smith Mark Peter (Executive)

Company: SMITH & WESSON BRANDS, INC. (SWBI)

Report Date: 2026-05-01

Detailed Transactions and Holdings:

• Acquired 90,956 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: A | equity_swap_involved: false | shares_owned_after: 604,340.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 23,473 shares of Common Stock at $15.57 per share (Direct)
  Date: 2026-05-01 | Code: F | equity_swap_involved: false | shares_owned_after: 580,867.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 4,481 shares of Common Stock at $14.97 per share (Direct)
  Date: 2026-05-02 | Code: F | equity_swap_involved: false | shares_owned_after: 576,386.00 | transaction_form_type: 4 | Footnotes: F3
• Acquired 181,912 shares of Performance Rights (Derivative)
  Date: 2026-05-01 | Code: A | Expires: 2029-05-01 | equity_swap_involved: false | shares_owned_after: 181,912.00 | transaction_form_type: 4 | Footnotes: F4, F4

Footnotes:

• F1: 1/4th of the RSUs shall vest on each of the first, second, third, and fourth annual anniversaries of the date of grant. Shares, net of tax withholding, will be delivered on each applicable vesting date.
• F2: Includes 342 shares acquired under the Issuer's Employee Stock Purchase Plan on September 30, 2025 and 1,607 shares acquired under the Issuer's Employee Stock Purchase Plan on March 31, 2026.
• F3: Represents shares of common stock withheld by the Issuer to satisfy certain tax withholding obligations associated with the vesting of restricted stock units.
• F4: Each performance right represents a contingent right to recieve one share of the Issuer's common stock. The performance rights vest based on achievement of certain target performance of the Issuer's stock price over a three year period. The number represents the maximum number of shares that may be delivered pursuant to the award.
• REMARKS: The reporting person is President and Chief Executive Officer.